Evidence-Based Medical News

Mode

All Oncology Infectious Disease Neurology Psychiatry Cardiology Diabetes & Endocrinology Pediatrics Allergy & Immunology Rheumatology Primary Care & Family Medicine Gastroenterology Nutrition & Obesity Medicine Orthopedics & Sports Medicine OB/GYN & Women's Health Radiology & Imaging Genetics & Precision Medicine Anesthesiology & Pain Medicine Pulmonology & Critical Care Physical Medicine & Rehab Nephrology Emergency Medicine Urology Ophthalmology Hematology Dermatology Geriatrics & Aging ENT (Otolaryngology) Palliative Care

Research

Clinical Trials Drug Pipeline Weekly Digests

Reference

Conditions Medications

Community

Text Size

Log in / Sign up

apixaban

14 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of apixaban

51 trials tracked of apixaban: 24 in phase 3 or 4 and 12 with published results. The most-cited published study has 1058 citations.

51Trials tracked

24Phase 3 & 4

0Recruiting

12With published results

Phase distribution

Phase 4 9 Phase 3 15 Phase 2 8 Phase 1 7 Other / NA 12

Phase 3 Apixaban for the Treatment of Venous Thromboembolism in Patients With Cancer Completed · 1,058 cited
Phase 3 Apixaban or Dalteparin in Reducing Blood Clots in Patients With Cancer Related Venous Thromboembolism Completed · 589 cited
Phase 4 Trial to Evaluate Anticoagulation Therapy in Hemodialysis Patients With Atrial Fibrillation Completed · 230 cited
Phase 4 Study Of The Blood Thinner, Apixaban, For Patients Who Have An Abnormal Heart Rhythm (Atrial Fibrillation) And Expected To Have Treatment To Put Them Back Into A Normal Heart Rhythm (Cardioversion) Completed · 172 cited
Phase 3 Apixaban in Preventing Secondary Cancer Related Venous Thrombosis in Cancer Patients Who Have Completed Anticoagulation Therapy Completed · 56 cited
Phase 3 A Study of the Safety and Effectiveness of Apixaban in Preventing Blood Clots in Children With Leukemia Who Have a Central Venous Catheter and Are Treated With Asparaginase Completed · 53 cited

Show 44 more trials

Phase 4 Apixaban Versus Warfarin in the Evaluation of Progression of Atherosclerotic Calcification and Vulnerable Plaque Completed · 46 cited
Phase 4 Assessment of an Education and Guidance Programme for Eliquis Adherence in Non-Valvular Atrial Fibrillation (AEGEAN) Completed · 33 cited
Phase 3 Apixaban for Early Prevention of Recurrent Embolic Stroke and Hemorrhagic Transformation Completed · 32 cited
Phase 3 Apixaban Versus Warfarin for the Management of Post-operative Atrial Fibrillation Completed · 22 cited
Phase 4 Apixaban for Primary Prevention of Venous Thromboembolism in Patients With Multiple Myeloma Completed · 16 cited
Phase 4 A Study of Apixaban in Patients With Atrial Fibrillation, Not Caused by a Heart Valve Problem, Who Are at Risk for Thrombosis (Blood Clots) Due to Having Had a Recent Coronary Event, Such as a Heart Attack or a Procedure to Open the Vessels of the Heart Completed · 10 cited
Phase 4 Multi-center Study to Evaluate the Safety of Apixaban (BMS-562247) in Indian Subjects Undergoing Elective Total Knee Replacement or Total Hip Replacement Surgery Completed
Phase 4 Apixaban Pharmacokinetics in Bariatric Patients (APB) Completed
Phase 4 Apixaban for the Acute Treatment of Venous Thromboembolism in Children Completed
Phase 3 AStudy To Evaluate Safety And Eficacy Of Apixaban In Japanese Acute Deep Vein Thrombosis (DVT) And Pulmonary Embolism (PE) Patients Completed
Phase 3 RAMBLE - Rivaroxaban vs. Apixaban for Heavy Menstrual Bleeding Completed
Phase 3 Study of an Investigational Drug for the Prevention of Thrombosis-related Events Following Hip Replacement Surgery (ADVANCE-3) Completed
Phase 3 Study of an Investigational Drug for the Prevention of Thrombosis-related Events Following Knee Replacement Surgery Completed
Phase 3 Efficacy and Safety Study of Apixaban for Extended Treatment of Deep Vein Thrombosis or Pulmonary Embolism Completed
Phase 3 A Phase III Study of Apixaban in Patients With Atrial Fibrillation Completed
Phase 3 Efficacy and Safety Study of Apixaban for the Treatment of Deep Vein Thrombosis or Pulmonary Embolism Completed
Phase 3 Study of Apixaban for the Prevention of Thrombosis-related Events in Patients With Acute Medical Illness Completed
Phase 3 Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation Completed
Phase 2 Safety Study of Apixaban in Recent Acute Coronary Syndrome Completed
Phase 2 Evaluation of the Hemocompatibility of the Direct Oral Anti-Coagulant Apixaban in Left Ventricular Assist Devices Completed
Phase 2 A Healthy Volunteer Pharmacokinetics (PK)/Pharmacodynamics (PD), Safety and Tolerability Study of Andexanet in Healthy Japanese and Caucasian Subjects Completed
Phase 2 A Phase 2 Pilot Study of Apixaban for the Prevention of Thromboembolic Events in Patients With Advanced (Metastatic) Cancer Completed
Phase 2 Phase 2 Study of Apixaban Reversal by Ciraparantag as Measured by WBCT Completed
Phase 2 A Phase 2 Study To Evaluate The Safety Of Apixaban In Atrial Fibrillation Completed
Phase 2 Study to Gather Information About the Proper Dosing of the Oral FXIa Inhibitor BAY 2433334 and to Compare the Safety of the Study Drug to Apixaban, a Non-vitamin K Oral Anticoagulant (NOAC) in Patients With Irregular Heartbeat (Atrial Fibrillation) That Can Lead to Heart-related Complications. Completed
Phase 2 A Study of the Safety and Pharmacokinetics of Apixaban Versus Vitamin K Antagonist (VKA) or Low Molecular Weight Heparin (LMWH) in Pediatric Subjects With Congenital or Acquired Heart Disease Requiring Anticoagulation Completed
Phase 1 Pharmacokinetics and Pharmacodynamics of Apixaban in Subjects on Hemodialysis Completed
Phase 1 Bioavailability of Apixaban Crushed Tablet Completed
Phase 1 Phase 1 Oral Solution and Crushed Tablet Relative Bioavailability Study of Apixaban When Administered Through a Nasogastric Tube in Healthy Subjects Completed
Phase 1 A Study to Assess the Effects of 2 Prothrombin Complex Concentrates on the Pharmacodynamics of Apixaban in Healthy Adult Subjects Completed
Phase 1 Phase 1 Bioavailability Study of Apixaban Solution Formulation Relative to Apixaban Tablets in Healthy Subjects Completed
Phase 1 A Study to Evaluate Safety and PK of Multiple Doses of LT3001 Drug Product and Drug-drug Interaction in Healthy Subjects Completed
Phase 1 Phase 1 Oral Solution Bioavailability Study of Apixaban When Administered Through a Nasogastric Tube in Healthy Subjects Completed
N/A Safety and Effectiveness of Apixaban Compared to Warfarin in Secondary Prevention in Patients With Atrial Fibrillation Completed
N/A Treatment Patterns and Bleeding Risk of Anticoagulants in Patients With Venous Thromboembolism in Korea Completed
N/A Medical Need of OAC Reversal Completed
N/A Prediction of the COBRRA AF Anticoagulant Trial in Healthcare Claims Data Completed
N/A Non-interventional, Retrospective Cohort Study to Explore OAC Treatment in Korea Completed
N/A Effectiveness And Safety Of Oral Anticoagulants Among Obese Patients With Non-Valvular A-Fib In VA Patients With Medicare Completed
N/A A Study to Learn About the Effects of Medicines That Help in Thinning the Blood in People With Atrial Fibrillation (AF) Between 2016 and 2020 in France Completed
N/A Direct Oral Anticoagulants (DOACs) Versus LMWH +/- Warfarin for VTE in Cancer Completed
N/A Safety and Effectiveness of Apixaban in Very Elderly Patients With Non-valvular Atrial Fibrillation (NVAF) Compared to Warfarin Using Administrative Claims Data Completed
N/A Treatment Patterns Among Patients With Venous Thromboembolism in the United States Completed
N/A Apixaban Drug Utilization Study In Stroke Prevention In Atrial Fibrillation (Spaf) Completed

Showing the 50 most-cited and recently-updated of 51 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

‹ Prev 1 2